Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines.
Aluminum-adjuvanted vaccines are administered through an intramuscular injection (IM) in the US and EU, however, a subcutaneous injection (SC) has been recommended in Japan because of serious muscle contracture previously reported following multiple IMs of antibiotics. Newly introduced adjuvanted vaccines, such as the human papillomavirus (HPV) vaccines, have been recommended through IM. In the present study, currently available vaccines were evaluated through IM in mice. Aluminum-adjuvanted vaccines induced inflammatory nodules at the injection site, which expanded into the intra-muscular space without any muscle degeneration or necrosis, whereas non-adjuvanted vaccines did not. These nodules consisted of polymorph nuclear neutrophils with some eosinophils within the initial 48h, then monocytes/macrophages 1 month later. Inflammatory nodules were observed 6 months after IM, had decreased in size, and were absorbed 12 months after IM, which was earlier than that after SC. Cytokine production was examined in the injected muscular tissues and AS04 adjuvanted HPV induced higher IL-1β, IL-6, KC, MIP-1, and G-CSF levels in muscle tissues than any other vaccine, but similar serum cytokine profiles were observed to those induced by the other vaccines. Currently available vaccines did not induce muscular degeneration or fibrotic scar as observed with muscle contracture caused by multiple IMs of antibiotics in the past.
Department of Pediatrics, Tokyo Medical University, Tokyo 160-0023, Japan.
Yasuyo
Y
Kashiwagi
Kitasato Institute for Life Sciences, Laboratory of Viral Infection, Tokyo 108-8641, Japan.
Mika
M
Maeda
Department of Pediatrics, Tokyo Medical University, Tokyo 160-0023, Japan.
Hisashi
H
Kawashima
Kitasato Institute for Life Sciences, Laboratory of Viral Infection, Tokyo 108-8641, Japan. Electronic address: tetsuo-n@lisci.kitasato-u.ac.jp.
Tetsuo
T
Nakayama
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000535:Aluminum / Q000008:administration & dosage*; D000818:Animals; D016207:Cytokines / Q000276:immunology; D004804:Eosinophils / Q000276:immunology; D007249:Inflammation / Q000276:immunology*; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009000:Monocytes / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D052097:Quadriceps Muscle / Q000473:pathology; D014611:Vaccination / Q000009:adverse effects; D014612:Vaccines / Q000009:adverse effects* / Q000276:immunology
D000276:Adjuvants, Immunologic; D016207:Cytokines; D014612:Vaccines; D000535:Aluminum
Aluminum adjuvant; Cytokines; Intramuscular injection; Monophosphoryl lipid A (MPL); Muscle contracture; Subcutaneous injection